U.S. markets closed
  • S&P Futures

    4,014.00
    +10.75 (+0.27%)
     
  • Dow Futures

    34,069.00
    +83.00 (+0.24%)
     
  • Nasdaq Futures

    11,840.50
    +34.75 (+0.29%)
     
  • Russell 2000 Futures

    1,847.00
    +5.10 (+0.28%)
     
  • Crude Oil

    77.69
    +0.76 (+0.99%)
     
  • Gold

    1,786.50
    +5.20 (+0.29%)
     
  • Silver

    22.62
    +0.20 (+0.91%)
     
  • EUR/USD

    1.0515
    +0.0018 (+0.17%)
     
  • 10-Yr Bond

    3.5990
    +0.0930 (+2.65%)
     
  • Vix

    20.75
    +1.69 (+8.87%)
     
  • GBP/USD

    1.2213
    +0.0019 (+0.15%)
     
  • USD/JPY

    136.4780
    -0.2070 (-0.15%)
     
  • BTC-USD

    17,049.23
    -184.40 (-1.07%)
     
  • CMC Crypto 200

    403.11
    -8.10 (-1.97%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,838.82
    +18.42 (+0.07%)
     

Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.

Event:

Oppenheimer Rare & Orphan Disease Summit

Date:

May 21, 2021

Time:

Live Presentation 10:45 AM – 11:25 AM (ET)

The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.